ATE361668T1 - Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung - Google Patents

Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung

Info

Publication number
ATE361668T1
ATE361668T1 AT98910038T AT98910038T ATE361668T1 AT E361668 T1 ATE361668 T1 AT E361668T1 AT 98910038 T AT98910038 T AT 98910038T AT 98910038 T AT98910038 T AT 98910038T AT E361668 T1 ATE361668 T1 AT E361668T1
Authority
AT
Austria
Prior art keywords
tumor suppressor
chemotherapy
gene therapy
suppressor gene
combined tumor
Prior art date
Application number
AT98910038T
Other languages
English (en)
Inventor
Loretta Nielsen
Jo Horowitz
Daniel Maneval
G Demers
Mary Rybak
Gene Resnick
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Application granted granted Critical
Publication of ATE361668T1 publication Critical patent/ATE361668T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
AT98910038T 1997-02-18 1998-02-17 Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung ATE361668T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80175597A 1997-02-18 1997-02-18
US80176597A 1997-02-18 1997-02-18
US3806597P 1997-02-18 1997-02-18
US80168197A 1997-02-18 1997-02-18
US80128597A 1997-02-18 1997-02-18
US4783497P 1997-05-28 1997-05-28

Publications (1)

Publication Number Publication Date
ATE361668T1 true ATE361668T1 (de) 2007-06-15

Family

ID=27556335

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98910038T ATE361668T1 (de) 1997-02-18 1998-02-17 Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung

Country Status (18)

Country Link
EP (1) EP0969720B1 (de)
JP (1) JP2001511815A (de)
KR (2) KR100620939B1 (de)
CN (1) CN1248731C (de)
AT (1) ATE361668T1 (de)
AU (1) AU737621B2 (de)
BR (1) BR9807418A (de)
CA (1) CA2282683A1 (de)
CZ (1) CZ298488B6 (de)
DE (1) DE69837754T2 (de)
ES (1) ES2287974T3 (de)
HU (1) HUP0004326A3 (de)
IL (2) IL131447A0 (de)
NO (1) NO993943L (de)
NZ (1) NZ337283A (de)
PL (1) PL193767B1 (de)
SK (1) SK285969B6 (de)
WO (1) WO1998035554A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
CZ15498A3 (cs) 1995-07-17 1998-07-15 Board Of Regents, The University Of Texas System Konstrukce pro expresi pl6 a její aplikace při léčení rakoviny
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US20060275781A1 (en) 2004-11-03 2006-12-07 Introgen Therapeutics Inc. Novel method for the protection and purification of adenoviral vectors
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
CZ298511B6 (cs) * 1997-12-22 2007-10-24 Schering Corporation Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení
EP1082419A2 (de) * 1998-04-22 2001-03-14 Inex Pharmaceuticals Corp. Kombinationstherapie mit nucleinsäuren und konventionellen wirkstoffe
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AU3735100A (en) * 1999-03-19 2000-10-09 Schering Corporation Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
ATE481640T1 (de) * 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
EP1340498A1 (de) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Verwendung von Epothilonen zur Behandlung von mit proliferativen Prozessen assoziierten Gehirnerkrankungen
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
WO2005082396A2 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
KR100809890B1 (ko) * 2003-12-24 2008-03-06 가부시키가이샤 로코모젠 암 억제 방법
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CN108030931A (zh) * 2017-03-07 2018-05-15 大连民族大学 一种药物脂质体/p53基因复合物的应用
CN109200295A (zh) * 2018-10-08 2019-01-15 蚌埠医学院 一种用于治疗卵巢癌的药物组合物及其制备方法
EP4483886A1 (de) * 2023-06-30 2025-01-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Rna-verbindungen zur behandlung proliferativer erkrankungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
IL111257A0 (en) * 1993-10-15 1994-12-29 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
MY119007A (en) * 1995-12-22 2005-03-31 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases.

Also Published As

Publication number Publication date
WO1998035554A2 (en) 1998-08-20
JP2001511815A (ja) 2001-08-14
CZ293399A3 (cs) 2000-03-15
PL193767B1 (pl) 2007-03-30
CZ298488B6 (cs) 2007-10-17
KR20050113287A (ko) 2005-12-01
HUP0004326A3 (en) 2003-07-28
SK112299A3 (en) 2000-12-11
KR100620939B1 (ko) 2006-09-06
EP0969720A2 (de) 2000-01-12
AU6438098A (en) 1998-09-08
IL195605A0 (en) 2011-08-01
EP0969720A4 (de) 2004-05-12
WO1998035554A3 (en) 1998-11-26
DE69837754D1 (de) 2007-06-21
PL335334A1 (en) 2000-04-25
KR20000071185A (ko) 2000-11-25
NO993943L (no) 1999-10-15
AU737621B2 (en) 2001-08-23
CN1248731C (zh) 2006-04-05
NZ337283A (en) 2001-02-23
ES2287974T3 (es) 2007-12-16
DE69837754T2 (de) 2008-02-07
KR100688409B1 (ko) 2007-03-02
BR9807418A (pt) 2002-01-22
HUP0004326A2 (hu) 2001-02-28
IL131447A0 (en) 2001-01-28
HK1026579A1 (en) 2000-12-22
SK285969B6 (sk) 2007-12-06
CA2282683A1 (en) 1998-08-20
NO993943D0 (no) 1999-08-17
CN1252689A (zh) 2000-05-10
EP0969720B1 (de) 2007-05-09

Similar Documents

Publication Publication Date Title
ATE361668T1 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
DE69840216D1 (de) Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BR9907736A (pt) Agentes terapêuticos catalisados por enzima
MXPA01003344A (es) Composiciones y metodos para inmunoterapia especifica de wt1.
DE69837393D1 (de) Stimulierung von hämatopoietischen zellen im vitro
NO973838D0 (no) DNA-molekyler, deres fremstilling samt anvendelse ved genterapi
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
TR199802649A2 (xx) Sikline ba�l� kinazlar�n inhibit�rleri i�in ba�lama e�leri.
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
TR200102985T2 (tr) Gen tedavisi teknikleri.
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
PL327066A1 (en) Method of diagnosing and treating squamous cell carcinomas
PT1100528E (pt) Utilizacao de novos agentes indutores de morte celular em sinergia com os interferoes
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
BR0012301A (pt) Inibidores de crescimento de células epiteliais
DE69735676D1 (de) Proteinmarker für ösophaguskrebs
WO2003104401A3 (en) TARGETED CANCER GENE IN CHEMOTHERAPY
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
DE60024442D1 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie
WO2003105783A3 (en) CANCER-ASSOCIATED GENE AS A TARGET FOR CHEMOTHERAPY

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties